Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024

Key Takeaway: SI-BONE, Inc. will participate in the Barclays 26th Annual Global Healthcare Conference on March 12, 2024, where management will host a fireside chat. The company, a leader in surgical treatment for musculoskeletal disorders of the sacropelvic anatomy, has performed more than 95,000 procedures. Investors can access the conference call live and will have an opportunity to replay it afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE demonstrates commitment to innovation by presenting at a major healthcare conference.
  • The company has significant experience with over 95,000 sacropelvic procedures performed.
  • Management is actively engaging with investors through a formal presentation.

Full Press Release Details

SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Barclays 26th Annual Global Healthcare Conference in Miami. Management will be hosting a fireside chat on Tuesday, March 12, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://cc.webcasts.com/barc002/031224a_js/?entity=98_6MGR7KT. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Investor Contact: Saqib Iqbal investors@si-bone.com

Frequently Asked Questions

When is SI-BONE participating in the Barclays Healthcare Conference?

SI-BONE will participate in the conference on March 12, 2024, at 8:30 a.m. ET.

How can I listen to the SI-BONE conference call?

Investors can register for the conference call at the provided link on their site.

What is SI-BONE known for?

SI-BONE is a leader in minimally invasive surgical treatment for sacropelvic disorders.

How many sacropelvic procedures has SI-BONE supported?

SI-BONE has supported over 95,000 sacropelvic procedures since 2009.

Where can I find more information about SI-BONE?

Additional information is available on SI-BONE's official website, si-bone.com.

Last updated: Mar 4, 2024